News & Events

Founded in 2013, Cyclica is the first biological company to use the structure based AI platform to conduct diversified pharmacological research, and is also a typical high-tech company under China Canada cross-border ecological cooperation. The company has gathered a world top team with profound industry experience, a first-class platform and an innovative cooperation model, and is committed to using biophysics and artificial intelligence (AI) to help the pharmaceutical industry carry out faster, safer and lower cost drug research and development.

Its core platforms include Ligand Design and Ligand Express, which are screened by proteome for in-depth learning technology MatchMaker ™ And POEM for predicting molecular properties ™ Technical support. Cyclica’s platform has designed new compounds, and prioritized new compounds through multi pharmacological properties and analytical properties.

The picture shows the drug screening and design workflow of Cyclica Ligand Design and Ligand Express. Ligand Design and Ligand Express can be designed together to design the latest lead like molecules, so as to minimize unnecessary miss target effects, and comprehensively understand the molecular activity through integrated system biology and structural drug genomics. Cyclica’s differentiation platform provides new opportunities for drug discovery, including multi target drug design, lead compound optimization, ADMET attribute prediction, target deconvolution and drug reuse for various indications.

Cyclica believes that avant-garde drug discovery methods at the scientific and commercial levels can effectively reduce the failure rate of drug discovery and shorten the clinical time. Therefore, this round of financing will support Cyclica to continue to develop its proteome centered drug discovery platform, and further extend its cooperation with pharmaceutical manufacturers, as well as enter into adjacent fields, such as agricultural chemistry. In addition, this financing will support Cyclica’s academic cooperation project, the Cyclica Academic Partnerships Program (CAPP), and help cyclica and first-class academic research institutions to jointly establish a joint venture, thus promoting the development of cyclica’s business strategy in the diverse therapeutic field.

Based on more than 30 drug R&D projects, Cyclica will continue to stimulate innovation through venture capital and cooperation with early and emerging biotechnology companies. Cyclica’s recent partners include EntheogeniX Biosciences, NineteenGale Therapeutics, Rosetta Therapeutics, Rare Diseases Medicine Accelerator, a joint venture with Mannin Research, as well as two hidden joint ventures and more than 50 projects targeting multiple treatment fields.

The picture is: Cyclica was selected into the 2017 Zhongguancun U30 International Youth Innovation Award

In 2015, Cyclica won the angel round investment of China Canada Angel Alliance (CCAA for short) managed by Zhongguancun Dahe Capital, and was selected into Zhongguancun Dahe Capital CAMP China Canada Joint Venture Camp for international virtual incubation; In May 2017, Cyclica performed well in the Zhongguancun U30 overseas special session, won the 2017 Zhongguancun U30 International Youth Innovation Award, and became a typical high-tech enterprise under China Canada cross-border ecological cooperation.

Wang Tong, founding partner of Zhongguancun Dahe Capital, said that when it first invested in Cyclica, the company had only a few customers. Today, Cyclica has established cooperation with well-known research institutions and pharmaceutical enterprises in North America, Asia Pacific, Europe, South America and other places. The companies that have been publicized include WuXi AppTec, South Korea Yuhan Pharmaceutical, Brazil Eurofarma, Bayer, Germany Merck, etc., and are highly recognized by the partners, It confirms the strength of Cyclica. At the same time, as a typical representative of overseas projects related to the Chinese market invested by CCAA, and driven by Zhongguancun Dahe Capital, Cyclica carried out international cooperation with the Institute of Materia Medica of the Chinese Academy of Medical Sciences at the beginning of this year to jointly promote the drug screening process of COVID-19, becoming a typical example of international collaborative anti epidemic.

Dr. Srinivas Rao, CEO of EntheogeniX Biosciences and CSO of ATAI Life Sciences, said: “The computing platform of Cyclica has saved many months for our project, and has successfully designed completely novel and synthetic lead compounds. In the cooperation with Cyclica, their team is flexible, efficient and enthusiastic, which has always been the key driving force for our rapid development.”

Molly Bonakdarpour, a partner of Drive Capital, said, “What attracted us to join Cyclica is their creativity and unique business model. They have created a diversified portfolio of assets in various fields of indications through cooperation models, and continue to cooperate with multinational companies. Cyclica is helping the world to build a number of first-class biotechnology companies, but also improving their probability of success.”

Co founder of Cyclica Naheed Kurji, President and CEO, said: “The core of the spirit of Cyclica is to help patients by using a comprehensive and personalized approach to promote better drug discovery and development. We cooperate with innovative biotechnology companies to achieve this grand vision. We provide support to our partners through the platform of Cyclica and the team of applied scientists, and help them expand their scale through derivative companies and joint ventures. Through joint efforts, we are creating Build biotechnology R&D pipeline.